Navigation Links
Sundia's Animal Facility Passed Client and Government Inspection
Date:6/16/2009

SHANGHAI, June 16 /PRNewswire-Asia/ -- Sundia MediTech Company, a Shanghai-based integrated pharmaceutical contract research company, announced today that its animal facility in Shanghai has passed the audit from a major European Pharmaceutical Company. The Sundia management and staff are praised for providing good facilities and programs for the care and use of laboratory animals.

The inspection and audit took place in May. The entire animal facility and life studies were inspected and audited. As stated in its official approval letter: "Our overall impression of Sundia is very positive. The personnel handling animals are well trained and engaged. All procedures are well described in SOPs, and the site is very well organized." As a result of an extensive on-site evaluation, the major European pharmaceutical company determined that Sundia MediTech animal facility is committed to the highest level of animal care and research practices.

Sundia has strong institutional commitment to the animal care and use program. The Institutional Animal Care and Use Committee (IACUC) is led by CEO, Dr. Xiaochuan Wang. The state-of-art animal facility was designed by SinoPharma Group Wuhan Institute. The operation of the animal facility has followed the extensive Standard Operating Procedures (SOP) and guidelines, and all records are well maintained. The animal facility was evaluated by Shanghai Animal Management Committee, and the Permit for Using Laboratory Animals was obtained in January this year.

"The success of passing the audit demonstrated our effort to provide quality animal care for pharmaceutical research," said Dr. Jun Wang, Vice President of Biology at Sundia MediTech. "We are very pleased to receive such high praise from the leading major pharmaceutical company on the care and use of laboratory animals. It demonstrates the quality of our laboratory testing and the competence of our technicians," commented Dr. Xiaochuan Wang, CEO of Sundia.

About Sundia MediTech.

Sundia MediTech is a leading integrated pharmaceutical contract research organization (CRO) company. As a customer-focused company, Sundia MediTech provides integrated drug discovery service to more than 80 top pharmaceutical companies worldwide, ranging from early hit screening, biological service, lead optimization, DMPK, candidate preclinical development, API manufacturer, regulatory submission. For more information, please visit http://www.sundia.com .


'/>"/>
SOURCE Sundia Meditech Company, Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
2. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
3. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
4. Odyssey Thera Granted U.S. Patent for Animal Imaging
5. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
6. Researchers use magnetism to target cells to animal arteries
7. Smithfield Foods, Inc. Statement Regarding Animal Cloning
8. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
9. Animal Protection Groups Condemn FDAs Endorsement of Animal Cloning
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):